Scarica l'app Stockscreener
174.10
1.70%
-3.01
Dopo l'orario di chiusura:
174.00
-0.10
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$177.11
Aprire:
$174.5
Volume 24 ore:
1.57M
Relative Volume:
1.30
Capitalizzazione di mercato:
$17.51B
Reddito:
$3.10B
Utile/perdita netta:
$668.60M
Rapporto P/E:
26.77
EPS:
6.5044
Flusso di cassa netto:
$831.30M
1 W Prestazione:
+0.00%
1M Prestazione:
+8.98%
6M Prestazione:
+31.63%
1 anno Prestazione:
+30.45%
Intervallo 1D:
$172.03
$175.88
Intervallo di 1 settimana:
$172.03
$181.18
Portata 52W:
$122.14
$181.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
174.10 | 17.81B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
16.49 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.86 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.18 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.39 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.57 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com - Investing.com Canada
Neurocrine Biosciences chief legal officer sells $1.79m in stock - Investing.com
Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares - Stock Titan
NBIX Maintained by BMO Capital -- Price Target Raised to $170 - GuruFocus
Truist raises Neurocrine Bio stock price target on pipeline potential - Investing.com
Truist raises Neurocrine Bio stock price target on pipeline potential By Investing.com - Investing.com Canada
Reasons why investors should consider betting on Neurocrine stock - MSN
Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left? - simplywall.st
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen - ChartMill
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill
Form 144 NEUROCRINE BIOSCIENCES For: 10 July By Investing.com - Investing.com South Africa
Form 144 NEUROCRINE BIOSCIENCES For: 10 July - Investing.com India
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline - FXEmpire
Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing - Moomoo
Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy? - simplywall.st
Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com - Investing.com India
Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com - Investing.com South Africa
Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NEUROCRINE BIOSCIENCES For: 9 July By Investing.com - Investing.com Nigeria
10,000 NBIX shares listed for sale; recent Darin Lippoldt 10b5-1 trades (NBIX) - Stock Titan
Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - The Independent Record
Neurocrine Biosciences stock stays supported by a growing movement disorder portfolio - AD HOC NEWS
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run - Sahm
Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs - Yahoo Finance
Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study - Yahoo Finance
Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4 - Yahoo Finance
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight - Yahoo Finance
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Neurocrine Biosciences outlines its neurology focus as a mid-cap biotech name - AD HOC NEWS
Insider option exercise and 10b5-1 sales at NBIX (NBIX) - Stock Titan
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - AOL.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD By Investing.com - Investing.com Nigeria
Neurocrine Biosciences stock hits all-time high at 176.1 USD - Investing.com
Neurocrine Biosciences stock and its role in neurological treatments - AD HOC NEWS
RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating - Moomoo
Reasons Why Investors Should Consider Betting on Neurocrine Stock - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside - DirectorsTalk Interviews
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen - ChartMill
NBIXNeurocrine Biosciences Inc Options - Finviz
What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders - Sahm
Neurocrine Biosciences Inc (NBIX) Stock Up 3.9% and Still Underv - GuruFocus
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Delaet Ingrid | Chief Regulatory Officer |
Jul 09 '26 |
Option Exercise |
103.52 |
8,433 |
872,984 |
24,658 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 07 '26 |
Option Exercise |
103.52 |
3,401 |
352,072 |
19,626 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 08 '26 |
Option Exercise |
103.52 |
2,737 |
283,334 |
18,962 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 09 '26 |
Sale |
178.72 |
8,433 |
1,507,135 |
16,225 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 07 '26 |
Sale |
178.57 |
3,401 |
607,305 |
16,225 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 08 '26 |
Sale |
178.54 |
2,737 |
488,672 |
16,225 |
0.74%
2.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):